Great businesses at fair prices — here's why each makes the list.
…and 358 more buy candidates in the full briefing.
40 name(s) sliding toward Avoid:
Value $107,871 ▲ +7.9% since 2026-07-16 · ▼ -$41 (-0.0%) since yesterday · S&P +1.8% · Cash $3,897
| Stock | Held | Price | Today | Since buy | Grade |
| CF | 83 sh | $130.03 | ▲ +3.4% | +0.3% | 89 |
| EOG | 78 sh | $144.96 | ▲ +0.3% | +7.6% | 88 |
| FHI | 156 sh | $63.65 | ▼ -1.9% | +6.2% | 92 |
| HIG | 73 sh | $137.38 | ▼ -0.3% | +0.5% | 90 |
| INTU | 33 sh | $359.30 | ▲ +3.2% | +21.9% | 86 |
| LOPE | 69 sh | $148.13 | ▼ -1.4% | +3.5% | 90 |
| LULU | 85 sh | $120.26 | ▼ -0.5% | +1.2% | 88 |
| NBIX | 58 sh | $154.03 | ▼ -1.2% | -10.2% | 89 |
| PRI | 31 sh | $287.65 | ▼ -1.3% | -8.0% | 93 |
| RMD | 49 sh | $240.10 | ▲ +1.8% | +18.4% | 84 |
Fictional money · prices update daily · a live test of whether the picks actually work.
Does the grading actually work? Two honest halves — a backtest on past data, and the real live record as it ripens. It reports the truth even when that's “not enough data yet.”
Reconstructed 320 graded moments across 150 companies (a sample of 150 names), then measured what each actually returned over the next 12 months.
Do higher grades earn better returns?
| Grade | Names | 12-mo return | vs S&P |
| A (80-100) | 44 | +13.5% | -0.5% |
| B (65-79) | 161 | +11.8% | -3.6% |
| C (50-64) | 91 | +12.9% | -1.7% |
| D-F (<50) | 24 | +41.0% | +27.2% |
→ higher grades did WORSE here (gap 27.5 pts) ⚠️
32 snapshot(s) since 2026-07-06, none ripe yet — first 6-month check ~2027-01-06.
Backtest limits: ~5 years back, surviving companies only, restated statements — a strong first read, not gospel. The live record is the hindsight-free gold standard and strengthens every month. Refreshed 2026-08-30. Educational only — not financial advice.
Market weather: FAIR (SPY above its rising 200-day average).
Earnings on September 3 — significant risk of a guidance cut. Multiple sources report that lululemon is expected to lower its fiscal 2026 outlook when it reports Q2 on Wednesday. UBS identified weakness in both the U.S. and China. The company already slashed full-year revenue growth expectations from 2–4% to flat-to-down-1% after Q1, and analysts worry another cut is coming because the current guide still assumes a second-half improvement that hasn't materialized. Gross margins have slipped to ~55.6% from over 58% a year ago. Goldman Sachs flagged "persistent pressure on demand, weak consumer sentiment, increased promotions, and potential slowing growth in China." Brand fatigue and a perceived lack of innovation are additional headwinds. Dick's Sporting Goods also just lowered guidance citing sector-wide challenges, adding to the negative read-across.
This is a real near-term risk. The grade (88.2) reflects strong historical financials, but it can't see forward into a potential guidance cut. If you're considering LULU, it may be worth waiting until after the Sept 3 report to see how the numbers land.
CFO placed on administrative leave amid stock-trading probe. Multiple outlets report that LOPE's CFO has been put on administrative leave in connection with a stock-trading investigation. This is a governance red flag — it doesn't necessarily mean wrongdoing has occurred, but it introduces uncertainty and possible legal/regulatory risk. The grade (89.5) reflects LOPE's excellent financials (zero net debt, 31% ROE, 20% margins), and those numbers haven't changed. But governance issues can weigh on a stock regardless of fundamentals. Worth monitoring closely; if charges or SEC action follow, this could become a serious flag.
(Note: the article source was a Google News redirect; the headline and multiple corroborating sources — including Simply Wall St — confirm the story.)
Two positive pipeline developments. (1) The FDA accepted Neurocrine's IND application for NBI-1117567, a Phase 2 Alzheimer's cognition drug developed through its Nxera partnership. Early-stage but strategically important — Alzheimer's is a massive unmet need. (2) Crenessity (for congenital adrenal hyperplasia) continues to ramp fast: $337 million in H1 2026 sales, up ~400% year-over-year, with only ~15% of diagnosed patients prescribed so far. The doctor base has nearly tripled. One risk: Vertex just agreed to acquire rival Crinetics for $10B, bringing a competing CAH candidate into well-funded hands.
The grade reflects NBIX's strong growth (rev CAGR 24%, EPS CAGR 46%) and the Crenessity ramp validates it. Pipeline expansion into Alzheimer's is a long-term option, not a near-term catalyst. The stock has pulled back ~15% over the past month, which may partly explain the attractive valuation score.
Broke ground on Blue Point One, the world's largest low-carbon ammonia plant. CF Industries, JERA Co. (35%), and Mitsui & Co. (25%) began construction on the $3.7 billion facility in Louisiana. CF holds a 40% stake. The plant will produce 1.4 million metric tons of ammonia annually and capture ~98% of CO2 generated. Production is expected to begin in 2029. CF is also investing an additional $550 million in shared infrastructure for future expansion.
This is a strategically significant long-term investment that positions CF in the emerging clean-ammonia/energy-transition market. It won't move near-term earnings, but it signals management confidence and diversifies the revenue base beyond traditional fertilizer. Separately, Freedom Broker downgraded CF on nitrogen pricing concerns — a fair near-term headwind, but the grade already accounts for current valuation.
Fiscal 2027 Q1 results beat guidance; buybacks support valuation. Deckers filed an SEC 8-K (material event) and multiple sources indicate the company's fiscal Q1 topped guidance. Buyback activity continues to support the stock. However, the broader footwear/apparel sector is under pressure — Dick's Sporting Goods' weak guidance and a Barron's "footwear apocalypse" headline weigh on sentiment. The grade (87.6) reflects DECK's strong profitability and brand moat (Hoka, UGG). Near-term sector noise, but fundamentals remain solid.
(Note: the SEC 8-K filing itself returned a 403 error when accessed; the summary above relies on the surrounding coverage.)
Truist downgraded to Hold on weak new Term Life sales; valuation looks fair. The most material PRI headline is the Truist analyst downgrade from Buy to Hold, citing underperformance in new Term Life policy sales. Separately, a valuation analysis found PRI trading at a P/E of ~11.7x vs. a modeled fair value of 11.4x — essentially fairly priced, not offering clear upside. Institutional buying continues (Corient, Deutsche Bank, Kingsview all adding shares).
The grade (92.9) is the highest in the focused set, driven by exceptional health, profitability, and valuation scores. The Truist downgrade is worth noting — if new policy sales continue to lag, growth could slow — but the fundamentals remain strong and the valuation is undemanding. News doesn't override the grade; this is context alongside a very high score.
Q2 revenue growth led its peer group; still screens cheap after a 123% five-year run. Hartford reported $7.26B in Q2 revenue, up 8.1% YoY — the fastest growth among multi-line peers. However, it missed on book value per share and the stock dipped ~2% post-earnings. Despite the 123% run, HIG still trades at a P/E of ~9.1x vs. an industry average of 11.3x. Five of six valuation metrics say the stock is below typical expectations. The key question: is this genuine value or a value trap if claims costs rise?
The grade (90.3) agrees — valuation scores a perfect 100 and growth is strong. The book-value miss bears watching but isn't alarming on its own.
Digital asset expansion + strong momentum, but stretched by some measures. FHI is up 23% YTD, driven by tokenized money-market fund initiatives and blockchain partnerships. One analyst narrative pegs fair value at $59.86 (suggesting ~8% overvaluation at $64), while a DCF model puts it at $71.37. Fee pressure and heavy reliance on money-market products are risks.
The grade (91.5) reflects rock-solid financials and a reasonable valuation on a P/E basis (~12x). The digital-asset angle is an interesting growth option but speculative. No material negative news.
Insider selling + dividend declared; valuation near fair. Raymond James' chief admin officer sold $1.33M in shares — notable but routine for a senior executive. The company also declared its regular quarterly dividend. Valuation is mixed: an excess-returns model suggests a ~31% discount to intrinsic value, while the P/E (15x) is roughly in line with peers. RJF has delivered 108% total returns over five years. Fundamentals are strong (19% ROE); the risk is any sustained pressure on client activity or fee margins.
No material operational news — the insider sale is a data point, not a red flag on its own.
No material company-specific news. Headlines are mostly institutional fund-flow updates (Wellington, Two Sigma adjusting positions) and a CEO speaking engagement at SUPER DUG. Analysts have a consensus "Hold" rating. The grade reflects strong financials for an oil & gas producer with low leverage and good cash returns.
Priced a $400 million stock offering at $56.50/share — dilutive. TXNM issued ~7.08 million new shares to raise ~$400M, with proceeds going to repay an existing $400M term loan. This is dilutive to existing shareholders (more shares outstanding for the same business), though the balance sheet does improve. Separately, Blackstone investors are involved in a deal related to PNM (TXNM's subsidiary), adding complexity.
The low grade (46.1) already reflects weak fundamentals. The equity issuance to refinance debt is a sign of financial strain, not strength.
Debt strain is the headline concern. Whirlpool's net-debt-to-EBITDA ratio is elevated, and the company just issued $2 billion in high-coupon secured notes — a sign of difficulty refinancing cheaply. Revenue and EPS face multi-year pressure. The 115-year anniversary marketing campaign is nice branding but doesn't address the financial headwinds. Analysts have a consensus "Reduce" rating.
The grade (45.3) captures this: weak health, weak growth, stressed balance sheet. News confirms the picture.
Seeking Alpha published a bullish take citing raised guidance and a stronger storage business. This is a contrarian view — the grade (45.5) flags Ormat for weak valuation and slow growth relative to its price. A single bullish article doesn't change the quantitative picture. Institutional buying continues (HSBC, Manulife, Canada Pension Plan all adding shares), which is worth noting as smart-money activity, but the grade says the stock is expensive for what it delivers.
No material company-specific news. Headlines are institutional fund-flow updates and a listicle about dividend REITs. Analysts have a consensus "Hold." The low grade reflects valuation and growth concerns typical of net-lease REITs in the current rate environment.
No material company-specific news. Institutional buying/selling headlines only. A Simply Wall St article suggests IRM "could be 13% undervalued on its data center growth narrative," but the grade (39.2) — the lowest in the focused set — disagrees strongly. The valuation pillar likely flags the stock as expensive relative to its financial fundamentals regardless of the data-center narrative.
No article was fetched for Dollar Tree, but the rating flipped from Hold to Buy based on the grade crossing the 70 bar. This was a marginal upgrade (70.8 is just above the line).
Honest limits: Google News redirect URLs could not be followed directly — headlines from those sources were confirmed via corroborating articles elsewhere. The SEC 8-K filing for DECK returned a 403 error and could not be read directly; the summary relies on surrounding coverage. One article (Santa Fe New Mexican on TXNM/PNM) returned a 429 rate-limit error and could not be read. This digest covers free, publicly available sources read on the morning of 2026-09-01; it is research context, not financial advice.
MarketMind is a personal, educational stock-research tool. Every morning it screens roughly 900 large- and mid-cap U.S. companies, grades each one from 0–100 on five research-backed pillars — financial health, profitability, growth, valuation, and moat — and surfaces the businesses that look strong and reasonably priced.
The idea it rests on: over the long run, a stock's price follows the company's profits. So rather than chasing hype, MarketMind looks for great businesses at fair prices and lets time do the work.
It also runs a Paper Fund — a fictional $100,000 that automatically follows the tool's own Buy ratings — so you can watch, over time, whether the picks actually work. It's pretend money: nothing here is ever bought or sold for real.
Built with free public data · refreshed every morning at 7:00 AM U.S. Central time.